Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.35
- Piotroski Score 3.00
- Grade Neutral
- Symbol (NTLA)
- Company Intellia Therapeutics, Inc.
- Price $16.53
- Changes Percentage (3.31%)
- Change $0.53
- Day Low $15.61
- Day High $16.56
- Year High $34.87
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $109.00
- High Stock Price Target $252.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.37
- Trailing P/E Ratio -4.23
- Forward P/E Ratio -4.23
- P/E Growth -4.23
- Net Income $-481,192,000
Income Statement
Quarterly
Annual
Latest News of NTLA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History
Intellia Therapeutics is hosting two investor events in November 2024, including the release of third quarter financial results and new clinical data for nexiguran ziclumeran. This news comes amidst o...
By Yahoo! Finance | 3 days ago -
Intellia reports positive data from Phase II study of NTLA-2002 for HAE
Intellia Therapeutics announces positive results from Phase I/II trial of NTLA-2002, a CRISPR-based gene therapy for hereditary angioedema. Promising reduction in monthly attack rates and potential fo...
By Yahoo! Finance | 2 weeks ago -
Xander Schauffele and Patrick Cantlay forming a cornerstone for American team golf
Xander Schauffele and Patrick Cantlay's success in team competitions like the Ryder Cup and Presidents Cup signals a new era for American golf....
By AP NEWS | 1 month ago
